Pharsight

Axiron is owned by Eli Lilly And Co.

Axiron contains Testosterone.

Axiron has a total of 7 drug patents out of which 0 drug patents have expired.

Axiron was authorised for market use on 23 November, 2010.

Axiron is available in solution, metered;transdermal dosage forms.

Axiron can be used as a method of transdermal administration of a physiologically active agent to a subject., a method of transdermally delivering testosterone, a method of increasing the testosterone blood level of a person in need thereof, a method of increasing the testosterone blood level of an adult male subject in need thereof.

The generics of Axiron are possible to be released after 27 September, 2027.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784878	ELI LILLY AND CO	Transdermal delivery rate control using amorphous pharmaceutical compositions	Jul, 2023 (5 months from now)
US8993520	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Jun, 2026 (3 years from now)
US9180194	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Jun, 2026 (3 years from now)
US8807861	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8419307	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US9289586	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8435944	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Sep, 2027 (4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of transdermal administration of a physiologically active agent to a subject.; A method of increasing the testosterone blood level of a person in need thereof

Dosage: SOLUTION, METERED;TRANSDERMAL